Nanobiotix S.A. (NBTX): History, Ownership, Mission, How It Works & Makes Money

Interested in a company pioneering a unique approach to cancer treatment? Have you heard of Nanobiotix S.A. (NBTX), a French-based nanomedicine company focused on enhancing the efficacy of radiation therapy? With a market capitalization of €151.695 million as of April 2025, and key partnerships with industry giants like Johnson & Johnson, Nanobiotix is striving to transform cancer treatment on a global scale. Keep reading to explore Nanobiotix's history, ownership structure, mission, technology, and revenue streams, and discover how this innovative company aims to revolutionize cancer treatment.

Nanobiotix S.A. (NBTX) History

Nanobiotix S.A. Founding Timeline

Year established

Nanobiotix S.A. was established in 2003.

Original location

The company was originally located in Paris, France.

Founding team members

The founding team members included:

• Laurent Levy

Initial capital/funding

Nanobiotix secured its initial seed funding from Laurent Levy in 2003, followed by a fundraising event with private investors in 2005.

Nanobiotix S.A. Evolution Milestones

Nanobiotix S.A. Transformative Moments

Nanobiotix has undergone several transformative moments that have significantly shaped its trajectory:

• Strategic Shift to Immuno-Oncology: Nanobiotix expanded its focus to include immuno-oncology, leveraging its Nanobiotix technology to enhance the effectiveness of immune checkpoint inhibitors.
• Global Expansion: The company has expanded its operations globally, establishing partnerships and collaborations with leading cancer centers and pharmaceutical companies in the United States, Europe and Asia.
• Regulatory Milestones: The receipt of regulatory designations such as Fast Track and Breakthrough Therapy designations from regulatory agencies like the FDA has accelerated the development and review of Nanobiotix’s product candidates.

To gain further insights into the company's guiding principles, explore Mission Statement, Vision, & Core Values of Nanobiotix S.A. (NBTX).

Nanobiotix S.A. (NBTX) Ownership Structure

Understanding the ownership structure of Nanobiotix S.A. is crucial for investors and stakeholders, providing insights into who controls the company and how its governance is managed.

Nanobiotix S.A.'s Current Status

Nanobiotix S.A. is a public company, trading on the Euronext Paris exchange under the ticker symbol NBTX and on the Nasdaq Global Select Market under NBTX. This means that a portion of the company is owned by public shareholders.

Nanobiotix S.A.'s Ownership Breakdown

The ownership of Nanobiotix S.A. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. While specific percentages may fluctuate due to market activity, it's helpful to consider a general overview of the ownership structure based on the most recent available data. The following table provides an illustrative example of potential ownership distribution; however, note that the exact figures can vary and should be verified with the latest filings.

Nanobiotix S.A.'s Leadership

The leadership team at Nanobiotix S.A. is responsible for the strategic direction and operational management of the company. Key members of the leadership team typically include:

• Chief Executive Officer (CEO): Leads the overall strategy and execution of the company's objectives.
• Chief Financial Officer (CFO): Manages the company's financial operations, including reporting, budgeting, and fundraising.
• Chief Medical Officer (CMO): Oversees clinical development and regulatory affairs.
• Chief Scientific Officer (CSO): Leads research and development efforts.

For detailed information on Nanobiotix S.A.'s financial health, you can refer to this analysis: Breaking Down Nanobiotix S.A. (NBTX) Financial Health: Key Insights for Investors

Nanobiotix S.A. (NBTX) Mission and Values

Nanobiotix S.A. is dedicated to pioneering physics-based therapeutic approaches to revolutionize cancer treatment outcomes, supported by a commitment to making a difference for humanity. The company's core values revolve around pushing the boundaries of what is known to expand possibilities for human life.

Core Purpose

Official mission statement

• Discovery of practice-changing therapeutics for major diseases through a physics-based approach, with the support of people committed to making a difference for humanity.
• Nanobiotix is dedicated to finding new treatments for cancer based on the combined application of nanotechnologies and biotechnologies.

Vision statement

• Nanobiotix aims to create products that will transform health outcomes for millions of people with cancer and other challenging diseases.
• Nanobiotix to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
• Join our mission to expand life for millions of patients worldwide.

Nanobiotix remains focused on advancing its lead program which is proceeding as planned. To enable further growth, Nanobiotix will leverage new nanotherapeutic technologies with the potential to improve treatment outcomes for millions of patients.

Company slogan/tagline

• Expanding life.
• Building new cancer therapies atom by atom.
• French roots, global outlook.

The holistic design aims to create connections between the company's “expanding life” motto and its proven science.

Related article: Exploring Nanobiotix S.A. (NBTX) Investor Profile: Who’s Buying and Why?

Nanobiotix S.A. (NBTX) How It Works

Nanobiotix S.A. (NBTX) is a late-stage clinical biotechnology firm that enhances cancer treatment effectiveness by employing nanoparticle technology to boost radiotherapy. The company's core focus is on developing and marketing innovative, nanotechnology-driven approaches to improve patient outcomes in cancer therapy.

Nanobiotix S.A.'s Product/Service Portfolio

Nanobiotix S.A.'s Operational Framework

Nanobiotix operates through a structured framework that integrates research, clinical development, regulatory approval, and commercialization. Key aspects of its operational processes include:

• Research and Development: Continues to innovate new applications for its nano-radiotherapy approach, exploring treatments for various cancers.
• Clinical Trials: Conducts clinical trials to demonstrate the safety and effectiveness of NBTXR3 and other product candidates.
• Regulatory Approval: Seeks regulatory approvals in key markets, such as the United States and Europe, to commercialize its products.
• Manufacturing: Oversees the manufacturing of its nanoparticle products to ensure quality and scalability.
• Commercialization: Establishes partnerships and distribution networks to market and sell its products to hospitals and cancer centers.

To gain more insights into the financial aspects, consider reading: Breaking Down Nanobiotix S.A. (NBTX) Financial Health: Key Insights for Investors.

Nanobiotix S.A.'s Strategic Advantages

Nanobiotix has several strategic advantages that enable its success in the competitive biotechnology industry:

• First-in-Class Technology: NBTXR3 is a first-in-class product that uses nanotechnology to enhance radiation therapy, providing a unique approach to cancer treatment.
• Strong Clinical Data: Clinical trials have demonstrated the potential of NBTXR3 to improve outcomes for patients with certain types of cancer.
• Experienced Management Team: Nanobiotix has an experienced management team with a track record of success in the biotechnology industry.
• Strategic Partnerships: The company has established partnerships with leading pharmaceutical companies and research institutions to develop and commercialize its products.

Nanobiotix S.A. (NBTX) How It Makes Money

Nanobiotix S.A., a late-stage clinical biotechnology firm, primarily generates revenue through strategic collaborations and licensing agreements centered on its innovative NanoXray technology. This technology enhances the effectiveness of radiotherapy in cancer treatment.

Nanobiotix S.A.'s Revenue Breakdown

As a clinical-stage company, Nanobiotix's revenue streams are currently centered around partnership agreements rather than direct product sales. The information below is based on the available financial data.

Nanobiotix S.A.'s Business Economics

Nanobiotix operates with a focus on research and development, primarily funded through venture capital and collaboration agreements. Here are key aspects of its business economics:

• R&D Investment: A significant portion of expenses is allocated to the research and development of NanoXray technology.
• Partnerships: Strategic alliances with pharmaceutical companies provide upfront payments, milestone payments, and potential royalties on future product sales.
• Operating Expenses: Includes costs related to clinical trials, regulatory approvals, and administrative functions.

Nanobiotix S.A.'s Financial Performance

Nanobiotix's financial status reflects its stage as a clinical biotechnology company. Key points include:

• Revenue: Revenues are primarily derived from collaboration agreements. For example, in 2023, Nanobiotix reported total revenue of €6.7 million, a decrease from €8.2 million in 2022. This revenue is recognized based on the progress of their partnership agreements.
• Net Loss: As of the fiscal year 2023, Nanobiotix reported a net loss of €43.5 million, compared to a net loss of €42.4 million in the previous year. These losses are typical for biotech companies in the clinical stage due to high R&D expenditures.
• Cash Reserves: Nanobiotix closely manages its cash flow to fund ongoing operations and clinical trials. As of December 31, 2023, cash and cash equivalents totaled €27.4 million.
• Financial Outlook: The company's financial performance is closely tied to its ability to secure and advance collaboration agreements, achieve clinical milestones, and manage its operating expenses effectively.

To gain more insights into the financial health of Nanobiotix S.A. (NBTX), you might find this resource helpful: Breaking Down Nanobiotix S.A. (NBTX) Financial Health: Key Insights for Investors

Nanobiotix S.A. (NBTX) Market Position & Future Outlook

Nanobiotix S.A. is strategically positioned within the competitive landscape of cancer treatment, focusing on innovative approaches like radioenhancement. The company's future outlook hinges on the successful development and commercialization of its NanoXray technology, particularly NBTXR3, and its ability to forge strategic partnerships to expand its market reach.

Competitive Landscape

Opportunities & Challenges

Industry Position

Nanobiotix occupies a unique niche within the oncology market with its NanoXray technology. However, it competes with larger, more established companies that offer a wider range of cancer treatment solutions.

• Nanobiotix is trying to establish itself as a leader in the emerging field of radioenhancement.
• The company's success depends on demonstrating the clinical and economic benefits of NBTXR3.
• Strategic partnerships and collaborations are crucial for Nanobiotix to expand its market reach and compete effectively.

For more insights into the investors and the reasons behind their investment decisions, check out: Exploring Nanobiotix S.A. (NBTX) Investor Profile: Who’s Buying and Why?